Found 4596 clinical trials
CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.
CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.
- 332 views
- 08 Nov, 2020
- 1 location
CCCWFU 99211: Feasibility of Delivering a quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
CCCWFU 99211: Feasibility of Delivering a quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
- 259 views
- 08 Nov, 2020
- 1 location
A STUDY TO EVALUATE A PANEL OF BLOOD BIOMARKERS FOR USE IN PATIENTS UNDERGOING EVALUATION FOR LUNG CANCER, ONC-LN-04
A STUDY TO EVALUATE A PANEL OF BLOOD BIOMARKERS FOR USE IN PATIENTS UNDERGOING EVALUATION FOR LUNG CANCER, ONC-LN-04
- 98 views
- 23 Nov, 2020
- 1 location
A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease
Obstructive Pulmonary Disease
- 112 views
- 25 Mar, 2021
- 1 location
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
- 1324 views
- 23 Nov, 2020
- 1 location
A Randomized, double-blind, parallel-group, 12-week, chronic-dosing, multi-center study to assess the efficacy and safety of PT010 compared to PT009 in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD).
obstructive pulmonary disease (COPD).
- 548 views
- 25 Mar, 2021
- 1 location
A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)
pulmonary disease (COPD)
- 612 views
- 25 Mar, 2021
- 1 location
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.
- 536 views
- 22 Nov, 2021
- 62 locations
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.
- 178 views
- 19 Feb, 2021
- 4 locations
VastBiome: The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods …
- 0 views
- 28 Feb, 2022
- 1 location